MATTHEW J. SWANIC, M.D.
STUDY INVESTIGATOR

CLINICAL RESEARCH TEAM:

***A*DVANCEMED CLINICAL RESEARCH**
8565 S. Eastern Avenue, Suite 102
Las Vegas, NV 89123

Phone: (702) 515-9648
Fax: (702) 761-3568

CLINIC SITES:

LAS VEGAS EYE INSTITUTE
9555 S. Eastern Avenue, Suite 260
Las Vegas, NV 89123

PROFESSIONAL EXPERIENCE:

***A*DVANCEMED CLINICAL RESEARCH – STUDY INVESTIGATOR** **2011 – PRESENT**
Works directly with the Sponsor to implement and manage pharmaceutical trials per protocol, FDA and ICH guidelines; Responsibilities are not limited to, but include patient recruitment and clinical trial management to ensure execution is per *A*dvanceMed Clinical Research Standard Operating Procedures, FDA Code of Federal Regulations and ICH Good Clinical Practices while maintaining confidentiality and strict guidelines for protection of human subjects per NIH.

LAS VEGAS EYE INSTITUTE – OWNER, PHYSICIAN AND SURGEON, CORNEAL SPECIALIST **2013 – PRESENT**

EYE CARE ASSOCIATES OF NEVADA – PHYSICIAN AND SURGEON, CORNEAL SPECIALIST **2011 – 2013**

PROFESSIONAL AFFILIATIONS:

- American Society of Cataract and Refractive Surgery **2009 – PRESENT**
- American Academy of Ophthalmology **2007 – PRESENT**

EDUCATION:

- Fellowship, Cornea and Refractive Surgery, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA **2011**
- Residency, Ophthalmology, Tufts New England Eye Center, Boston, MA **2010**
- Internship, Department of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV **2007**
- Doctor of Medicine, University of Nevada School of Medicine, Las Vegas, NV **2006**
- BS, Biology and Chemistry, University of Nevada Las Vegas – Honors College, **2002**

Las Vegas, NV

TRAININGS AND CERTIFICATIONS:

- NIDA CTN Good Clinical Practices Training & Certification **2023**
- FDA Guidances Training and Review **2023**
- ICH Guidances Training and Review **2023**
- FDA Code of Federal Regulations Training and Review **2023**
- AdvanceMed Clinical Research SOP Training and Review **2023**
- PHRP Protecting Human Research Participants Training & Certification **2022**
- OHRP Human Subject Assurance Training & Certification **2022**
- NIH Protecting Human Research Participants Training & Certification **2018**

HONORS AND AWARDS:

- Alpha Omega Alpha Honors Society **2005**
- Bachelor of Science Cum Laude (Honors College) **2000**

LICENSES:

NEVADA STATE MEDICAL LICENSE
License Number: 13823
Issued: 15/Feb/2011
Expires: 30/Jun/2025

PUBLICATIONS:

- Swanic MJ, Castro D, Mattox C, Krishnan C. Comparison of Average Retinal Nerve Fiber Layer Thickness Obtained with Cirrus and Stratus OCT in the Evaluation of Glaucoma Patients. ARVO May 5, 2009
- Swanic MJ, Strominger M. Grand Rounds at the New England Center- Myopic Strabismus Fixus. Ocular Surgery News. May 2009.
- Swanic MJ, Reichel E. Grand Rounds at the New England Center- Adult Onset Coats' Disease. Ocular Surgery News. November 25, 2008.
- Swanic MJ, Raizman MB. Grand Rounds at the New England Eye Center- Peripheral Ulcerative Keratitis. Ocular Surgery News. July 25, 2008.
- Swanic MJ, Krishnan C. Grand Rounds at the New England Eye Center- Herpetic Uveitis. Ocular Surgery news. November 15, 2007

CLINICAL RESEARCH EXPERIENCE:

GLK-311-01: Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects with Open-angle

Glaucoma or Ocular Hypertension. 2023, Principal Investigator

A Phase 3 Study Evaluating the Safety and Efficacy of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-3). 2023, Principal Investigator

A Multi-Center, Double-Masked, Randomized, Two-Arm, Parallel-Group, Safety and Efficacy Study to Compare Perrigo Pharmaceuticals International DAC Brinzolamide and Brimonidine Tartrate Ophthalmic Suspension 1%/0.2% to Novartis Pharmaceuticals Simbrinza® (brinzolamide/brimonidine tartrate 1%/0.2% ophthalmic suspension) in the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in both Eyes. 2021, Principal Investigator

A Phase IIb, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. 2020, Principal Investigator

A Phase IIb, randomized, double-masked, multicenter study to evaluate the safety and efficacy of ECF843 vs Vehicle in subjects with dry eye disease. 2020, Principal Investigator

A Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Bioequivalence Study with Clinical Endpoint Comparing Brinzolamide Ophthalmic Suspension 1% of Perrigo Pharma International DAC to Azopt® (brinzolamide ophthalmic suspension) 1% of Novartis Pharmaceuticals Corporation in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes. 2019, Principal Investigator

A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Glaucoma or Ocular Hypertension - Spectrum 3 Study. 2019, Principal Investigator.

A Phase III, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease (Stride 3). 2019, Principal Investigator.

A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with Glaucoma or Ocular Hypertension. 2018, Principal Investigator.

A prospective, double-masked, randomized, multicenter, placebo-controlled, parallel-group study assessing the safety and ocular hypotensive efficacy and optimum concentration to be used clinically of netarsudil ophthalmic solution in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in the United States. 2017, PI.

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients with a Chalazion. 2017, PI.

A prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to AR-13324 Ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005% in subjects with elevated intraocular pressure. 2016, Principal Investigator.

A Single-Masked, Non-interventional Study Assessing the Persistence of Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution 0.02% Once Daily Compared with Timolol Maleate Ophthalmic Solution 0.5% Twice Daily After the Completion of 12 Months of Dosing in Subjects with Elevated Intraocular Pressure. 2016, Principal Investigator.

A Phase III Multi-Center, Randomized, Double-Masked, Active- and Placebo-Controlled Study of Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma. 2015, Principal Investigator
A prospective, double-masked, randomized, multi-center, active-controlled, parallel-group 12-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in subjects with elevated intraocular pressure. 2015, Principal Investigator.

Evaluation of LME636 in the persistent relief of ocular discomfort in patients with severe dry eye disease. 2015, Principal Investigator.

A Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel, 12-Month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR13324 Ophthalmic Solution, 0.02% Q.D. and B.I.D. Compared to Timolol Maleate Ophthalmic Solution, 0.5% B.I.D. in patients with elevated intraocular pressure. 2014, Principal Investigator.

A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension. 2013, Principal Investigator.

A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma. 2013, Principal Investigator.

A Phase III Study to Determine the Efficacy and Safety of XXXX in Subjects with Dry Eye Syndrome. 2012, Principal Investigator.

A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution 0.77% Administered Once Daily. 2012, Principal Investigator.

A Phase III Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1%/ Brimonidine 0.2% compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension. 2011, Principal Investigator

A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome. 2011, Principal Investigator.